ReviewExpert review of hematology2016
Modulation of hepcidin to treat iron deregulation: potential clinical applications.
Review in Expert review of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- Identification and characterization of novel hepcidin mimetics that modulate ferroportin function.Blood red cells & iron · 2026Article
- Ferroptosis as a Novel Therapeutic Strategy to Overcome Multidrug Resistance in Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Modulation of hepcidin synthesis: the core link in the bi-directional relationship between iron and obesity.Reviews in endocrine & metabolic disorders · 2026Review
- Iron and Cancer.Advances in experimental medicine and biology · 2025Review
- Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency.Nutrients · 2024Article
- Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.NPJ science of food · 2024Review
- Iron Metabolism and Inflammatory Mediators in Patients with Renal Dysfunction.International journal of molecular sciences · 2024Review
- Iron-related Biomarkers in the Diagnosis and Management of Iron Disorders.Current medicinal chemistry · 2024Review
- High Hepcidin Levels Promote Abnormal Iron Metabolism and Ferroptosis in Chronic Atrophic Gastritis.Biomedicines · 2023Article
- Activation of the Hepcidin-Ferroportin1 pathway in the brain and astrocytic-neuronal crosstalk to counteract iron dyshomeostasis during aging.Scientific reports · 2022Article
- COVID-19 and Progesterone: Part 1. SARS-CoV-2, Progesterone and its potential clinical use.Endocrine and metabolic science · 2021Article
- Hepcidin Signaling in Health and Disease: Ironing Out the Details.Hepatology communications · 2021Review
- Iron Deficiency in Obesity and after Bariatric Surgery.Biomolecules · 2021Review
- ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?Journal of clinical medicine · 2021Review
- Involvement of Hepcidin in Cognitive Damage Induced by Chronic Intermittent Hypoxia in Mice.Oxidative medicine and cellular longevity · 2021Article
- Role of redox iron towards an increase in mortality among patients: a systemic review and meta-analysis.Blood research · 2019Review
- Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer.Antioxidants & redox signaling · 2019Article
- Hepcidin as a key iron regulator mediates glucotoxicity-induced pancreatic β-cell dysfunction.Endocrine connections · 2019Article
- Iron as a Central Player and Promising Target in Cancer Progression.International journal of molecular sciences · 2019Review
- The interplay between iron and oxygen homeostasis with a particular focus on the heart.Journal of applied physiology (Bethesda, Md. : 1985) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The secreted peptide hormone hepcidin regulates systemic and local iron homeostasis through degradation of the iron exporter ferroportin. Dysregulation of hepcidin leads to altered iron homeostasis and development of pathological disorders including hemochromatosis, and iron loading and iron restrictive anemias. Therapeutic modulation of hepcidin is a promising method to ameliorate these conditions. Several approaches have been taken to enhance or reduce the effects of hepcidin in vitro and in vivo. Based on these approaches, hepcidin modulating drugs have been developed and are undergoing clinical evaluation. In this article we review the rationale for development of these drugs, the data concerning their safety and efficacy, their therapeutic uses, and potential future prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.